PET imaging with 89Zr: From radiochemistry to the clinic

Nuclear Medicine and Biology

Volumn 40, Issue 1, 2013, Pages 3-14

  Deri, Melissa A ^a,b   Zeglis, Brian M ^a   Francesconi, Lynn C ^b   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

89Zr; Antibody; ImmunoPET; PET Imaging; Radiochemistry

Indexed keywords

LYSINE; THIOL; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89; DIAGNOSTIC AGENT; RADIOISOTOPE;

ANTIBODY LABELING; BIOCHEMICAL COMPOSITION; CHELATION; CONJUGATION; CRYSTAL STRUCTURE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; ISOTOPE ANALYSIS; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOISOTOPE DECAY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY;

ANIMALS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOISOTOPES; ZIRCONIUM;

EID: 84871928766     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.08.004     Document Type: Review

References (97)

1. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotech 2005, 23:1137-1146.
2. Wu A.M., Olafsen T. Antibodies for molecular imaging of cancer. Cancer J 2008, 14:191-197.
3. Zeglis B.M., Lewis J.S. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton T 2011, 40:6168-6195.
4. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010, 110:2858-2902.
5. Anderson C.J., Connett J.M., Schwarz S.W., Rocque P.A., Guo L.W., Philpott G.W., et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992, 33:1685-1690.
6. Cai W.B., Chen K., He L.N., Cao Q.H., Koong A., Chen X.Y. Quantitative PET of EGFR expression in xenograft-bearing mice using Cu-64-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol I 2007, 34:850-858.
7. 64Cu-DOTA-trastuzumab. Eur J Nucl Med Mol I 2009, 36:1510-1519.
8. Paudyal P., Paudyal B., Hanaoka H., Oriuchi N., Iida Y., Yoshioka H., et al. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET. Cancer Sci 2010, 101:1045-1050.
9. Carrasquillo J.A., Pandi-Taskar N., O'Donoghue J.A., Humm J.L., Zanzonico P., Smith-Jones P.M., et al. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med 2011, 52:1173-1180.
10. Verel I., Visser G.W.M., Vosjan M.J.W.D., Finn R., Boellaard R., Van Dongen G.A.M.S. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol I 2004, 31:1645-1652.
11. Dijkers E.C.F., Kosterink J.G.W., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunolPET imaging. J Nucl Med 2009, 50:974-981.
12. Munnink T.H.O., de Korte M.A., Nagengast W.B., Timmer-Bosscha H., Schroder C.P., de Jong J.R., et al. Zr-89-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010, 46:678-684.
13. Perk L.R., Visser G.W.M., Vosjan M., Stigter-van Walsum M., Tijink B.M., Leemans C.R., et al. Zr-89 as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals Y-90 and Lu-117 in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005, 46:1898-1906.
14. Perk L.R., Visser O.J., Walsum M.S.V., Vosjan M., Visser G.W.M., Zijlstra J.M., et al. Preparation and evaluation of Zr-89-Zevalin for monitoring of Y-90-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol I 2006, 33:1337-1345.
15. Holland J.P., Sheh Y.C., Lewis J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Bio 2009, 36:729-739.
16. Holland J.P., Williamson M.J., Lewis J.S. Unconventional Nuclides for Radiopharmaceuticals. Mol Imaging 2010, 9:1-20.
17. Vugts D.J., Van Dongen G. 89Zr-labeled compounds for PET imaging guided personalized therapy. Drug Discov Today 2011, 8:e53-e61.
18. Severin G.W., Engle J.W., Barnhart T.E., Nickles R.J. Zr-89 radiochemistry for positron emission tomography. Med Chem 2012, 7:389-394.
19. Hohn A., Zimmermann K., Schaub E., Hirzel W., Schubiger P.A., Schibli R. Production and separation of "non-standard" PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Q J Nucl Med Mol Im 2008, 52:145-150.
20. Zhang Y., Hong H., Cai W. PET tracers based on zirconium-89. Current Radiopharm 2011, 4:131-139.
21. Rice S.L., Roney C.A., Daumar P., Lewis J.S. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med 2011, 41:265-282.
22. Ikotun O.F., Lapi S.E. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. Future Med Chem 2011, 3:599-621.
23. Zeglis B., Lewis J.S. A practical guide to the construction of radiometallation bioconjugates for positron emission tomography. Dalton T 2011, 40:6168-6195.
24. Shore F.J., Bendel W.L., Brown H.N., Becker R.A. Radiations from Zr-89. Phys Rev 1953, 91:1203-1211.
25. Dejesus O.T., Nickles R.J. Production and purification of Zr-89, a potential PET antibody label. Appl Radiat Isotopes 1990, 41:789-790.
26. Ruggiero A., Holland J.P., Lewis J.S., Grimm J. Cerenkov luminescence imaging of medical isotopes. J Nucl Med 2010, 51:1123-1130.
27. Hinrichsen P.F. Decay of 78.4 h 89Zr. Nucl Phys A 1968, 118:538-544.
28. Meijs W.E., Herscheid J.D.M., Haisma H.J., Wijbrandts R., Vanlangevelde F., Vanleuffen P.J., et al. Production of highly pure no-carrier added Zr-89 for the labeling of antibodies with a positron emitter. Appl Radiat Isotopes 1994, 45:1143-1147.
29. Omara H.M., Hassan K.F., Kandil S.A., Hegazy F.E., Saleh Z.A. Proton induced reactions on Y-89 with particular reference to the production of the medically interesting radionuclide Zr-89. Radiochim Acta 2009, 97:467-471.
30. Zweit J., Downey S., Sharma H.L. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isotopes 1991, 42:199-201.
31. Dutta B., Maiti M., Lahiri S. Production of Zr-88, Zr-89 by proton induced activation of Y-nat and separation by SLX and LLX. J Radioanal Nucl Chem 2009, 281:663-667.
32. Verel I., Visser G.W.M., Boellaard R., Stigter-van Walsum M., Snow G.B., van Dongen G. Zr-89 immuno-PET: Comprehensive procedures for the production of Zr-89-labeled monoclonal antibodies. J Nucl Med 2003, 44:1271-1281.
33. Multi-Agency Radiological Laboratory Analytical Protocols Manual (NUREG-1576, Initial Report). 2004, p. 14-191.
34. Shannon R.D. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallogr A 1976, 32:751-767.
35. Ekberg C., Källvenius G., Albinsson Y., Brown P.L. Studies on the hydrolytic behavior of zirconium(IV). J Solution Chem 2004, 33:47-79.
36. Singhal A., Toth L.M., Lin J.S., Affholter K. Zirconium(IV) tetramer/octamer hydrolysis equilibrium in aqueous hydrochloric acid solution. J Am Chem Soc 1996, 118:11529-11534.
37. Lee D.B., Roberts M., Bluchel C.G., Odell R.A. Zirconium: biomedical and nephrological applications. ASAIO J 2010, 56:550-556.
38. Matsui S., Mitani M., Saito J., Tohi Y., Makio H., Matsukawa N., et al. A family of zirconium complexes having two phenoxy-imine chelate ligands for olefin polymerization. J Am Chem Soc 2001, 123:6847-6856.
39. Ning Y., Zhang Y., Rodriguez-Delgado A., Chen E.Y.X. Neutral metallocene ester enolate and non-metallocene alkoxy complexes of zirconium for catalytic ring-opening polymerization of cyclic esters. Organometallics 2008, 27:5632-5640.
40. Reznichenko A.L., Hultzsch K.C. C-2-Symmetric zirconium bis(amidate) complexes with enhanced reactivity in aminoalkene hydroamination. Organometallics 2010, 29:24-27.
41. Zhang Z.-H., Li T.-S. Applications of zirconium (IV) compounds in organic synthesis. Curr Org Chem 2009, 13:1-30.
42. Gornshtein F., Kapon M., Botoshansky M., Eisen M.S. Titanium and zirconium complexes for polymerization of propylene and cyclic esters. Organometallics 2007, 26:497-507.
43. Stephan D.W. Zirconium-phosphorus chemistry: Strategies in syntheses, reactivity, catalysis, and utility. Angew Chem Int Edit 2000, 39:314-329.
44. Pozhidaev A.I., Porai-Koshits M.A., Polynova T.N. Crystal structure of zirconium ethylenediaminetetraacetate tetrahydrate. J Struct Chem 1974, 15:548-553.
45. Ilyukhin A.B., Davidovich R.L., Samsonova I.N., Teplukhina L.V. Eightfold-coordinated diethylenetriaminepentaacetates: Crystal structures of K[M(Dtpa)]center dot 3H(2)O (M = Zr or Hf) and NH4[Sn(Dtpa)]center dot H2O. Crystallogr. Rep. 2000, 45:39-43.
46. Parker D., Pulukkody K., Smith F.C., Batsanov A., Howard J.A.K. Structures of the yttrium complexes of 1,4,7,10-tetraazacyclododecane-N, N[prime or minute], N[double prime], N[triple prime]-tetraacetic acid (H4dota) and N, N[double prime]-bis(benzylcarbamoylmethyl)diethylenetriamine-N, N[prime or minute], N[double prime]-triacetic acid and the solution structure of a zirconium complex of H4dota. J Chem Soc Dalton 1994, 689-693.
47. Martell A.E., Smith R.M. Critical Stability Constants 1974, Plenum Press, New York.
48. Baroncelli F., Grossi G. The complexing power of hydroxamic acids and its effect on the behaviour of organic extractants in the reprocessing of irradiated fuels-I the complexes between benzohydroxamic acid and zirconium, iron (III) and uranium (VI). J Inorg Nucl Chem 1965, 27:1085-1092.
49. Meijs W.E., Herscheid J.D.M., Haisma H.J., Pinedo H.M. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. Appl Radiat Isotopes 1992, 43:1443-1447.
50. Holland J.P., Divilov V., Bander N.H., Smith-Jones P.M., Larson S.M., Lewis J.S. Zr-89-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010, 51:1293-1300.
51. Koizumi M., Endo K., Kunimatsu M., Sakahara H., Nakashima T., Kawamura Y., et al. Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate an improved method. J Immunol Methods 1987, 104:93-102.
52. Meijs W.E., Haisma H.J., VanderSchors R., Wijbrandts R., VandenOever K., Klok R.P., et al. A facile method for the labeling of proteins with zirconium isotopes. Nucl Med Biol 1996, 23:439-448.
53. Lewis M.R., Shively J.E. Maleimidocysteineamido-DOTA Derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem 1998, 9:72-86.
54. Perk L.R., Vosjan M.J.W.D., Visser G.W.M., Budde M., Jurek P., Kiefer G.E., et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol I 2010, 37:250-259.
55. Vosjan M.J.W.D., Perk L.R., Visser G.W.M., Budde M., Jurek P., Kiefer G.E., et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010, 5:739-743.
56. Tinianow J.N., Gill H.S., Ogasawara A., Flores J.E., Vanderbilt A.N., Luis E., et al. Site-specifically Zr-89-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 2010, 37:289-297.
57. Zeglis B.M., Mohindra P., Weissmann G.I., Divilov V., Hilderbrand S.A., Weissleder R., et al. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand diels-alder click chemistry. Bioconjugate Chem 2011, 22:2048-2059.
58. Vugts D.J., Vervoort A., Stigter-van Walsum M., Visser G.W.M., Robillard M.S., Versteegen R.M., et al. Synthesis of phosphine and antibody-azide probes for in vivo staudinger ligation in a pretargeted imaging and therapy approach. Bioconjugate Chem 2011, 22:2072-2081.
59. McClinton L.T., Schubert J. The toxicity of some zirconium and thorium salts in rats. J Pharmacol Exp Ther 1948, 94:1-6.
60. Abou D.S., Ku T., Smith-Jones P.M. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol 2011, 38:675-681.
61. Mealey J. Turn-over of carrier-free zirconium-89 in Man. Nature 1957, 179:673-674.
62. Rama Sastry B.V., Owens L.K., Ball C.O.T. Differences in the distribution of zirconium-95 and niobium-95 in the rat. Nature 1964, 201:410-411.
63. CR F. The radiological hazards of zirconium-95 and niobium-95. Health Phys 1969, 16:209-220.
64. Meijs W.E., Haisma H.J., Klok R.P., vanGog F.B., Kievit E., Pinedo H.M., et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med 1997, 38:112-118.
65. Nagengast W.B., de Korte M.A., Munnink T.H.O., Timmer-Bosscha H., den Dunnen W.F., Hollema H., et al. (89)Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010, 51:761-767.
66. Keliher E.J., Yoo J., Nahrendorf M., Lewis J.S., Marinelli B., Newton A., et al. 89Zr-Labeled dextran nanoparticles allow in vivo macrophage imaging. Bioconjugate Chem 2011, 22:2383-2389.
67. Aerts H.J.W.L., Dubois L., Perk L., Vermaelen P., van Dongen G.A.M.S., Wouters B.G., et al. Disparity between in vivo EGFR expression and (89)Zr-labeled cetuximab uptake Assessed with PET. J Nucl Med 2009, 50:123-131.
68. Cohen R., Stammes M.A., de Roos I.H., Stigter-van Walsum M., Visser G.W., van Dongen G.A. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. Eur J Nucl Med Mol I 2011, 1:31.
69. Perk L.R., Visser G.W., Vosjan M.J., Stigter-van Walsum M., Tijink B.M., Leemans C.R., et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005, 46:1898-1906.
70. Hong H., Severin G.W., Yang Y., Engle J.W., Zhang Y., Barnhart T.E., et al. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol I 2012, 39:138-148.
71. Nagengast W.B., de Vries E.G., Hospers G.A., Mulder N.H., de Jong J.R., Hollema H., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48:1313-1319.
72. van Scheltinga A.G.T.T., van Dam G.M., Nagengast W.B., Ntziachristos V., Hollema H., Herek J.L., et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting a ntibodies. J Nucl Med 2011, 52:1778-1785.
73. Holland J.P., Normand G., Ruggiero A., Lewis J.S., Grimm J. Intraoperative imaging of positron emission tomographic radiotracers using cerenkov luminescence emissions. Mol Imaging 2011, 10:177-185.
74. Holland J.P., Caldas-Lopes E., Divilov V., Longo V.A., Taldone T., Zatorska D., et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab. PLoS One 2010, 5:e8859.
75. Verel I., Visser G.W.M., Boellaard R., Boerman O.C., van Eerd J., Snow G.B., et al. Quantitative Zr-89 immuno-PET for in vivo scouting of Y-90-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003, 44:1663-1670.
76. Verel I., Visser G.W.M., Boerman O.C., van Eerd J.E.M., Finn R., Boellaard R., et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiol 2003, 18:655-661.
77. Brouwers A., Verel I., Van Eerd J., Visser G., Steffens M., Oosterwijk E., et al. PET radioimmunoscintigraphy of renal cell cancer using Zr-89-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiol 2004, 19:155-163.
78. Heskamp S., van Laarhoven H.W.M., Molkenboer-Kuenen J.D.M., Franssen G.M., Versleijen-Jonkers Y.M.H., Oyen W.J.G., et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast Cancer model. J Nucl Med 2010, 51:1565-1572.
79. Munnink T.H.O., Arjaans M.E.A., Timmer-Bosscha H., Schroder C.P., Hesselink J.W., Vedelaar S.R., et al. PET with the Zr-89-labeled transforming growth factor-beta antibody fresolimumab in tumor models. J Nucl Med 2011, 52:2001-2008.
80. Perk L.R., Walsum M.S.-v, Visser G.W.M., Kloet R.W., Vosjan M.J.W.D., Leemans C.R., et al. Quantitative PET imaging of Met-expressing human cancer xenografts with Zr-89-labelled monoclonal antibody DN30. Eur J Nucl Med Mol I 2008, 35:1857-1867.
81. Ruggiero A., Holland J.P., Hudolin T., Shenker L., Koulova A., Bander N.H., et al. Targeting the internal epitope of prostate-specific membrane antigen with Zr-89-7E11 immuno-PET. J Nucl Med 2011, 52:1608-1615.
82. van Rij C.M., Sharkey R.M., Goldenberg D.M., Frielink C., Molkenboer J.D., Franssen G.M., et al. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med 2011, 52:1601-1607.
83. Nayak T.K., Garmestani K., Milenic D.E., Brechbiel M.W. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 2012, 53:113-120.
84. Walther M., Gebhardt P., Grosse-Gehling P., Wuerbach L., Irmler I., Preusche S., et al. Implementation of Zr-89 production and in vivo imaging of B-cells in mice with Zr-89-labeled anti-B-cell antibodies by small animal PET/CT. Appl Radiat Isotopes 2011, 69:852-857.
85. Vosjan M.J.W.D., Vercammen J., Kolkman J.A., Stigter-van Walsum M., Revets H., van Dongen G.A.M.S. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 2012, 11:1017-1025.
86. Nagengast W.B., Lub-de Hooge M.N., Oosting S.F., den Dunnen W.F.A., Warnders F.-J., Brouwers A.H., et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011, 71:143-153.
87. Hoeben B.A.W., Kaanders J.H.A.M., Franssen G.M., Troost E.G.C., Rijken P.F.J.W., Oosterwijk E., et al. PET of hypoxia with Zr-89-labeled cG250-F(ab')(2) in head and neck tumors. J Nucl Med 2010, 51:1076-1083.
88. Jacobson O., Zhu L., Niu G., Weiss I.D., Szajek L.P., Ma Y., et al. MicroPET imaging of integrin alpha(v)beta(3) expressing tumors using Zr-89-RGD peptides. Mol Imaging Biol 2011, 13:1224-1233.
89. Heneweer C., Holland J.P., Divilov V., Carlin S., Lewis J.S. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: Zr-89-albumin as a model system. J Nucl Med 2011, 52:625-633.
90. Avila-Rodriguez M.A., Selwyn R.G., Hampel J.A., Thornadsen B.R., DeJesus O.T., Converse A.K., et al. Positron-emitting resin microspheres as surrogates of Y-90 SIR-Spheres: a radiolabeling and stability study. Nucl Med Biol 2007, 34:585-590.
91. Heuveling D.A., Visser G.W.M., Baclayon M., Roos W.H., Wuite G.J.L., Hoekstra O.S., et al. Zr-89-Nanocolloidal albumin-based PET/CT lymphoscintigraphy for sentinel node detection in head and neck cancer: preclinical results. J Nucl Med 2011, 52:1580-1584.
92. Ruggiero A., Villa C.H., Holland J.P., Sprinkle S.R., May C., Lewis J.S., et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int J Nanomed 2010, 5:783-802.
93. Boerjesson P.K.E., Jauw Y.W.S., de Bree R., Roos J.C., Castelijns J.A., Leemans C.R., et al. Radiation dosimetry of Zr-89-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med 2009, 50:1828-1836.
94. Borjesson P.K.E., Jauw Y.W.S., Boellaard R., de Bree R., Comans E.F.I., Roos J.C., et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Rese 2006, 12:2133-2140.
95. Rizvi S.N.F., Visser O.J., Vosjan M.J.W.D., van Lingen A., Hoekstra O.S., Zijlstra J.M., et al. Biodistribution, radiation dosimetry and scouting of Y-90-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using Zr-89-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol I 2012, 39:512-520.
96. Dijkers E.C., Munnink T.H.O., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., et al. Biodistribution of Zr-89-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.
97. Dijkers E.C.F., Kosterink J.G.W., Rademaker A.P., Perk L.R., van Dongen G.A.M.S., Bart J., et al. Development and characterization of clinical-grade Zr-89-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009, 50:974-981.